Manning Paul B's Form 4 filing
Candel Therapeutics, Inc. (CADL) · filed Dec 18, 2024
- Accession no.
- 0000950170-24-137889
- Filed
- Dec 18, 2024
- Trade date
- Dec 16, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $7.50M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Manning Paul BCIK 0001494695 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 16, 2024 | Common Stock | PPurchaseAcquired | +500,000 | $6.00 | +$3,000,000 | 1,142,406 | Indirect | |
| Dec 16, 2024 | Common Stock | PPurchaseAcquired | +750,000 | $6.00 | +$4,500,000 | 1,303,752 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.